Being this an observational registry aiming at quantifying effect estimates without direct comparisons to literature benchmarks, the investigators relied on confidence interval profiling for sample size justification, without proceeding with formal power analysis. As the main analysis is a pooled analysis of patients with atrial fibrillation ablation, an overall and comprehensive analysis is planned as the primary analytical approach. Accordingly, the investigators computed that a target sample of 209 patients will enable the computation of reasonably precise 95% confidence intervals. Specifically, assuming a 12-month freedom from 72.5% AF/atrial flutter/atrial tachycardia recurrence at 1 year (in keeping with results of SMART-AF trial), confidence intervals computed with the adjusted Wald method would be 60% to 85% for a 209-patient sample (point estimate 151/209 [72.5%]).